Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02806947 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT02806947 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 127 participants.
The verdict
NCT02806947, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk stratification. This trial incorporates both a novel up front GVHD therapy (sirolimus) as well as a novel BMT CTN developed acute GVHD biomarker test.
Interventions
- DRUG Sirolimus
- DRUG Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02806947
The ClinicalTrials.gov registry entry for NCT02806947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT02806947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02806947 about?
NCT02806947 is a clinical study titled "A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)". The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined according to clinical and biomarker-based risk stratification. This trial inco...
What is the current status of trial NCT02806947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2016-10. Estimated completion is 2019-02-19.
What interventions are being tested in trial NCT02806947?
The interventions under investigation include: Sirolimus (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT02806947?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.